TABLE 4.
Characteristics and treatment outcomes of inpatients (n=142) having infection with MRSA at Patan Hospital, Lalitpur, Nepal, 2018–2020
| Demographic and clinical characteristics | Individuals with MRSA | |
|---|---|---|
|
| ||
| n | (%) | |
| Year | ||
| 2018 | 40 | (28) |
| 2019 | 75 | (53) |
| 2020 | 27 | (19) |
| Sex | ||
| Female | 68 | (48) |
| Male | 74 | (52) |
| Age group, years | ||
| <1 | 17 | (12) |
| 1–5 | 20 | (14) |
| 6–18 | 22 | (15) |
| 19–35 | 35 | (25) |
| 36–50 | 17 | (12) |
| 51–65 | 13 | (9) |
| >65 | 18 | (13) |
| Specimen | ||
| Blood | 10 | (7) |
| Body swab | 2 | (1) |
| Pus | 123 | (87) |
| Respiratory sample | 7 | (5) |
| Sensitive to antibiotic* | ||
| Cotrimoxazole | 101 | (72) |
| Gentamicin | 43 | (31) |
| Ciprofloxacin | 6 | (4) |
| Ofloxacin | 6 | (4) |
| Chloramphenicol | 122 | (86) |
| Erythromycin | 37 | (26) |
| Clindamycin | 53 | (37) |
| Doxycycline | 89 | (94) |
| Vancomycin | 42 | (100) |
| Azithromycin | 2 | (22) |
| Linezolid | 40 | (95) |
| New antibiotic introduced after laboratory drug-susceptible report | ||
| Yes | 105 | (74) |
| No | 37 | (26) |
| Treatment outcome | ||
| Cured | 9 | (6) |
| Improved | 124 | (87) |
| No change | 1 | (1) |
| Discharged against medical advice | 5 | (4) |
| Unknown | 3 | (2) |
* Not all samples were tested for antibiotic sensitivity; the proportion shown to be susceptible here is among those tested for antibiotic susceptibility.
MRSA = methicillin-resistant Staphylococcus aureus.